Cerevel Therapeutics Holdings Inc ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Cerevel Therapeutics Holdings Inc zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Cerevel Therapeutics Holdings Inc zu Deinem Portfolio hinzuzufügen.
PHILADELPHIA , May 20, 2024 /PRNewswire/ -- Shareholder protection law firm Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ("Cerevel") on behalf of the company's investors. On December 6, 2023, Cerevel announced that it had agreed to be acquired by AbbVie Inc. at a price of $45.00 per share in cash.
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders. Halper Sadeh encourages Cerevel shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (21...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is s...
Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.
AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to be on a buying spree AbbVie is willing to spend about $8.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.